Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis

BACKGROUND: Drug resistance remains a serious challenge to rituximab therapy in B-NHL (B cell non-Hodgkin’s lymphoma). CDC (complement-dependent cytotoxicity) has been proposed as a major antitumor mechanism of rituximab, and direct abrogation of CD59 function partially restores rituximab sensitivit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xiaowen, Du, Yiqun, Chen, Jianfeng, Zhu, Na, Yao, Jiamei, Zhang, Xin, Wang, Na, Sun, Yujing, Gao, Feng, Hu, Weiguo, Hou, Yingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692258/
https://www.ncbi.nlm.nih.gov/pubmed/34956875
http://dx.doi.org/10.3389/fonc.2021.751904
_version_ 1784618922016768000
author Ge, Xiaowen
Du, Yiqun
Chen, Jianfeng
Zhu, Na
Yao, Jiamei
Zhang, Xin
Wang, Na
Sun, Yujing
Gao, Feng
Hu, Weiguo
Hou, Yingyong
author_facet Ge, Xiaowen
Du, Yiqun
Chen, Jianfeng
Zhu, Na
Yao, Jiamei
Zhang, Xin
Wang, Na
Sun, Yujing
Gao, Feng
Hu, Weiguo
Hou, Yingyong
author_sort Ge, Xiaowen
collection PubMed
description BACKGROUND: Drug resistance remains a serious challenge to rituximab therapy in B-NHL (B cell non-Hodgkin’s lymphoma). CDC (complement-dependent cytotoxicity) has been proposed as a major antitumor mechanism of rituximab, and direct abrogation of CD59 function partially restores rituximab sensitivity with high efficacy. However, universal blockade of CD59 may have deleterious effects on normal cells. Sp1 regulates constitutive CD59 expression, whereas NF-κB and CREB regulate inducible CD59 expression. METHODS: Immunohistochemistry (IHC) assay was used to detect the expression levels of CD59 and other related molecules. Quantitative Real-time PCR (RT-PCR) analysis was used to explore the levels of transcripts in the original and resistant cells. We chose LY8 cells to test the effects of NF-κB and CBP/p300 inhibition on CD59 expression using flow cytometry (FACS). Immunoblotting analysis was employed to detect the effects of curcumin and POH. The in vitro and in vivo experiments were used to evaluate the toxicity and combined inhibitory effect on tumor cells of curcumin and POH. RESULTS: We demonstrated that herbal (curcumin and perillyl alcohol) blockade of NF-κB specifically suppresses the expression of inducible CD59 but not CD20, thus sensitizing resistant cells to rituximab-mediated CDC. Moreover, activation of NF-κB and CREB is highly correlated with CD59 expression in B-NHL tissues. CONCLUSIONS: Our findings suggest the potential of CD59 expression as a predictor of therapeutic efficacy of NF-κB inhibitors in clinical application as well as the rationality of a NF-κB inhibitor-rituximab regimen in B-NHL therapy.
format Online
Article
Text
id pubmed-8692258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86922582021-12-23 Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis Ge, Xiaowen Du, Yiqun Chen, Jianfeng Zhu, Na Yao, Jiamei Zhang, Xin Wang, Na Sun, Yujing Gao, Feng Hu, Weiguo Hou, Yingyong Front Oncol Oncology BACKGROUND: Drug resistance remains a serious challenge to rituximab therapy in B-NHL (B cell non-Hodgkin’s lymphoma). CDC (complement-dependent cytotoxicity) has been proposed as a major antitumor mechanism of rituximab, and direct abrogation of CD59 function partially restores rituximab sensitivity with high efficacy. However, universal blockade of CD59 may have deleterious effects on normal cells. Sp1 regulates constitutive CD59 expression, whereas NF-κB and CREB regulate inducible CD59 expression. METHODS: Immunohistochemistry (IHC) assay was used to detect the expression levels of CD59 and other related molecules. Quantitative Real-time PCR (RT-PCR) analysis was used to explore the levels of transcripts in the original and resistant cells. We chose LY8 cells to test the effects of NF-κB and CBP/p300 inhibition on CD59 expression using flow cytometry (FACS). Immunoblotting analysis was employed to detect the effects of curcumin and POH. The in vitro and in vivo experiments were used to evaluate the toxicity and combined inhibitory effect on tumor cells of curcumin and POH. RESULTS: We demonstrated that herbal (curcumin and perillyl alcohol) blockade of NF-κB specifically suppresses the expression of inducible CD59 but not CD20, thus sensitizing resistant cells to rituximab-mediated CDC. Moreover, activation of NF-κB and CREB is highly correlated with CD59 expression in B-NHL tissues. CONCLUSIONS: Our findings suggest the potential of CD59 expression as a predictor of therapeutic efficacy of NF-κB inhibitors in clinical application as well as the rationality of a NF-κB inhibitor-rituximab regimen in B-NHL therapy. Frontiers Media S.A. 2021-12-08 /pmc/articles/PMC8692258/ /pubmed/34956875 http://dx.doi.org/10.3389/fonc.2021.751904 Text en Copyright © 2021 Ge, Du, Chen, Zhu, Yao, Zhang, Wang, Sun, Gao, Hu and Hou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ge, Xiaowen
Du, Yiqun
Chen, Jianfeng
Zhu, Na
Yao, Jiamei
Zhang, Xin
Wang, Na
Sun, Yujing
Gao, Feng
Hu, Weiguo
Hou, Yingyong
Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
title Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
title_full Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
title_fullStr Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
title_full_unstemmed Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
title_short Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
title_sort herbal nf-κb inhibitors sensitize rituximab-resistant b lymphoma cells to complement-mediated cytolysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692258/
https://www.ncbi.nlm.nih.gov/pubmed/34956875
http://dx.doi.org/10.3389/fonc.2021.751904
work_keys_str_mv AT gexiaowen herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT duyiqun herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT chenjianfeng herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT zhuna herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT yaojiamei herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT zhangxin herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT wangna herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT sunyujing herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT gaofeng herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT huweiguo herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis
AT houyingyong herbalnfkbinhibitorssensitizerituximabresistantblymphomacellstocomplementmediatedcytolysis